Skip to content
Open access

Congenital myasthenic syndromes in a single center: demographic, clinical and genetic features

Oct 2026 · ANPAbstract_CBN26 · 0 citations

Abstract

Background: Congenital Myasthenic Syndromes (CMS) comprise a heterogeneous group of neuromuscular junction disorders of genetic etiology, with over 35 causative genes identified to date. The majority of cases exhibit an autosomal recessive inheritance pattern, although autosomal dominant mutations have been reported in rare instances. These genetic defects disrupt the physiology of the neuromuscular junction through mechanisms that impair pre-synaptic, synaptic, and post-synaptic membrane functions. Clinically, the disease is characterized by fatigability or fluctuating muscle weakness, most frequently affecting the facial, bulbar, and axial musculature. Methods: This is a cross-sectional study based on data collection from medical records and interviews with patients and their caregivers or legal guardians (for patients under 18 years of age). The study was conducted at the Hospital das Clínicas of UNICAMP and included patients with a confirmed diagnosis of CMS undergoing follow-up until January 2025. Informed Consent Forms were obtained from all participants or their legal guardians if appropriate. Results: Data of 21 patients from 19 families were analyzed. There were 17 (71.4%) women and 6 (28.6%) men. Among the 21 cases, 13 (61.9%) carried a homozygous mutation in the CHRNE gene, 4 in DOK7 (19.0%), and one case each in COLQ, CHRNA1, and DPAGT1. One case presented a heterozygous variant in the CHRNG gene. The most prevalent variant was c.130dup, identified in 12 (57.14%) CHRNE patients. The mean age was 30.46 ± 17.89 years, while the mean age at the onset was 1.09 ± 1.61 years. A significant interval between symptom onset and diagnostic confirmation was observed: the mean age at clinical diagnosis was 15.46 years, and the mean age at genetic diagnosis was 27.63 ±19.20 years. The most frequently reported initial symptoms were dysphagia (27.8%) and frequent falls (22.2%). Eleven patients (52.4%) reported motor developmental delay. Other early manifestations included ptosis, ophthalmoparesis, weak cry, generalized weakness, and stridor. Currently, the predominant symptoms are weakness (66.66%) and fatigue (14.28%), often accompanied by ptosis, diplopia, and myalgia. Regarding the neonatal period, only five patients presented birth complications, associated with mutations in the CHRNE (n=3), DOK7 (n=1), and CHRNG (n=1) genes. The primary event was early respiratory distress; of these, only one case was resolved with initial measures, while the others required ventilatory support and Intensive Care Unit admission. Presently, two patients, carrying mutations in the CHRNA1 and CHRNG genes, are dependent of continuous ventilatory support by invasive mechanical ventilation or BiPAP. Conclusion: In this Brazilian cohort, CMS were predominantly linked to CHRNE mutations. The identified diagnostic delay reinforces the need to expand early access to genetic testing and specialized counseling to ensure better functional outcomes for patients.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.